In this Issue:
Atezolizumab + enzalutamide vs enzalutamide alone in mCRPC
Abiraterone, prednisolone +/- enzalutamide for high-risk nmPC
Temporal trends of prostate cancer incidence and mortality in NZ
Stereotactic ablative radiotherapy in oligometastatic CRPC
Diagnostic yield of fusion MRI-guided vs cognitive-guided biopsy
Survival after radical prostatectomy vs radiation therapy for ductal carcinoma
Risk of prostate cancer after prior negative biopsies
Abiraterone + ADT or apalutamide vs apalutamide for CRPC
Hypofractionated radiotherapy and patient-reported outcomes
Predicting early outcomes of intermediate- and high-risk prostate cancer
Please login below to download this issue (PDF)